1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  

This page is powered by Blogger. Isn't yours?

Saturday, June 17, 2017

 

Researchers Identify Metabolite That Could Signal a Higher Risk of Developing Dementia and Alzheimer’s






















Higher levels of a molecule called anthranilic acid could signal that a person is at increased risk of developing dementia and Alzheimer’s disease, according to a study.

The research, “Association of amine biomarkers with incident dementia and Alzheimer’s disease in the Framingham Study,” was published in the journal Alzheimer’s & Dementia.

In a search for new biomarkers to diagnose and track the progression of dementia and Alzheimer’s, researchers analyzed levels of 217 molecules known as metabolites that circulate in blood.

They looked at blood samples from 2,067 people who participated in the Framingham Heart Study, which was conducted to identify risk factors for heart disease. Ninety-three people in a subgroup of patients developed dementia during a mean follow-up period of 15.6 years, they discovered. Their average age was 56.

Researchers then looked for an association between metabolite levels and the risk of a person developing the neurodegenerative diseases after 10 years.

Increased levels of anthranilic acid were associated with greater risk of dementia, the team discovered. Increased levels of the neurotransmitter glutamate and lower levels of taurine and hypoxanthine, a precursor of uric acid, also seemed to be associated with increased risk of developing dementia.

Importantly, anthranilic acid is known to be involved in glutamate excitotoxicity, a process in which glutamate damages neurons by promoting their excessive and unregulated activity.

Although the results are preliminary, researchers believe there are several reasons why the metabolites they identified show promise as biomarkers of dementia and Alzheimer’s.

“First, anthranilic acid is produced during the degradation of tryptophan, an essential amino acid,” Dr. Sudha Seshadri, the study’s senior author, said in a news release. “Interestingly, other compounds produced through the same reactions have been reported as protective or deleterious for neurons and could constitute valuable drug targets.

“Second, this potential marker could also be used to identify groups of persons at higher risk of developing dementia, which could improve the efficiency of clinical trials and, in the future, detect persons that would benefit the most from a preventive treatment.”

This study was the first to use information from the Framingham Heart Study to search for new biomarkers for dementia and Alzheimer’s.

Story Source: The above story is based on materials provided by ALZHEIMERSNEWSTODAY
Note: Materials may be edited for content and length

Labels: